OncoInsight
Latest round
- Series A
Last raised
- Jul 2021
Total raised
- $21M
Investors
- 8
About OncoInsight
Based in Seoul, South Korea and founded in 2017, OncoInsight develops and delivers NK cell therapy product candidates to cancer patients while building a platform developing immune cell therapy based on One-stop CAR (chimeric antigen receptor). CAR NK call therapy involves infusion of NK cells that have been genetically engineered to express a chimeric antigen receptor (CAR) to reprogram the NK cells. The company has secured mass production technology for anticancer immune cell therapy through its proprietary hematopoietic stem cell-derived NK cell differentiation and culture technology. In addition, based on the CAR-NK cell therapy development platform that introduced CAR specific to cancer cell antigen, it has a total of three anticancer immune cell therapy pipelines, including gastric cancer and triple-negative breast cancer target pipelines. The company's main pipeline OI-101, is a cancer-targeted immune cell therapy, which is currently developing lung cancer as its main indication and anticancer immune cell therapy pipelines, including CAR-NK cell therapies OI-201 and OI-203 for gastric cancer and triple-negative breast cancer.
Who invested in OncoInsight
8 investors across 2 rounds
See all investors in OncoInsight
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OncoInsight
Who invested in OncoInsight?
OncoInsight has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OncoInsight raised?
OncoInsight has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did OncoInsight last raise money?
OncoInsight's most recent round on record is a Series A, in Jul 2021.
What does OncoInsight do?
Based in Seoul, South Korea and founded in 2017, OncoInsight develops and delivers NK cell therapy product candidates to cancer patients while building a platform developing immune cell therapy based on One-stop CAR (chimeric antigen receptor).
Where is OncoInsight headquartered?
OncoInsight is headquartered in Seoul, South Korea.
Which VCs invest in companies like OncoInsight?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at OncoInsight's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like OncoInsight? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.